Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Nanopore Technologies, Bio-Techne Partner to Develop Carrier Screening Assay

NEW YORK – Oxford Nanopore Technologies and Bio-Techne said on Thursday that they have forged a collaboration to develop an integrated sequencing workflow for carrier screening.

The project will combine long-range PCR technology from Bio-Techne's Asuragen brand with Oxford Nanopore's sequencing capabilities. The companies plan to develop an integrated wet- and dry-lab kit for genotyping 11 genes essential for carrier screening, which will be configured modularly to accommodate multiple use cases, Oxford Nanopore said.

"As clinical labs face increased demand for more informative and equitable carrier screening tests, we look forward to being a trusted partner to help laboratories implement scalable assays for these and other variants by leveraging the best of AmplideX PCR and nanopore-based sequencing," Kim Kelderman, president of Bio-Techne's genomics and diagnostics segment, said in a statement.

"We are really pleased to be working with Asuragen to develop more robust, reliable and accessible options for reproductive health and carrier screening," Oxford Nanopore CEO Gordon Sanghera said in a statement.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.